Fife Business Awards

MOFgen shortlisted in the Fife Business Awards

We are delighted to announce that MOFgen have been shortlisted in the Fife Business Awards in the category Most Enterprising Start Up.

More information at www.fifechamber.co.uk/fife-business-awards

Arab Health Exhibition

MOFgen to exhibit at Arab Health exhibition

MOFgen will be exhibiting at Arab Health 29th Jan-1st Feb – we will be at stand H7.F30 in Hall 7.

More information on the exhibition at www.arabhealthonline.com

Medica 2017

MEDICA 2017

We are exhibiting at MEDICA 2017, Dusseldorf, Germany, 13th-16th Nov – come and see us in Hall 16, stand F04-1.
We will also be attending Arab Health, Dubai International Convention and Exhibition Centre, 29th Jan-1st Feb 2018.

MOFgen Featured on BBC’s Reporting Scotland

MOFgen Featured on BBC’s Reporting Scotland

MOFgen welcomed BBC Scotland’s science correspondent Kenneth MacDonald to their labs in St Andrews to record a feature for the BBC’s Scottish news programme Reporting Scotland. The feature highlighted how MOFgen is developing porous metal organic frameworks as deliver systems for antimicrobial and therapeutic agents and the positive impact the products can make in the fields of infection control and wound care.

The feature can be viewed at

http://www.bbc.co.uk/news/uk-scotland-scotland-business-38563180

Funding boost for award-winning spinout company

Funding Boost for Award-Winning Spinout Company

MOFgen Ltd, an award-winning University of St Andrews spinout company has received a major funding boost to take on the healthcare market.

The company, which is pioneering cutting-edge technology for coating medical devices, has received investment totalling £300,000 from Mercia Fund Management and the Scottish Investment Bank. The investment will allow MOFgen to further the commercialisation of its products that will reduce Healthcare Acquired Infections (HAIs), prevent procedural complications and improve healing rates.

This seed investment comes on the heels of MOFgen winning first prize in this year’s Royal Society of Chemistry Emerging Technologies Competition and marks the culmination of intensive technical and commercial development by the St Andrews-based team.

MOFgen was formed to commercialise research into the development of metal-organic frameworks (MOFs) for biomedical applications conducted in the laboratories of Prof Russell Morris at the University’s School of Chemistry.

MOFs are powdery solids with microscopic pores that can be loaded with antibacterial, wound healing and anti-thrombotic agents such as antibiotics, bioactive gases and metal ions. Acting like reservoirs, they can be incorporated into coatings on medical devices and wound dressings to provide slow and controlled release of the active agents during the lifetime of the product.

As well as improving the quality of patient care, reducing infection rates and reducing the added burden on NHS resources caused by lengthy and repeated hospitalisation, their novel and multifunctional mode of action is expected to help in the fight against antibiotic resistant bacteria and provide alternatives where patient intolerances to current coatings exist.

MOFgen is preparing a library of products that can be adapted for and used by its customers to enhance the performance of their own product lines. The technology has already been validated by key industry partners and will now begin to penetrate its first target markets: medical devices and consumer healthcare.

The new company is led by a strong team that combines expertise in the medtech market (Dr Yvonne Davies – CEO, and Dr Ian Muirhead – Chairman) and new technology commercialisation (Dr Stewart Warrender – Research and Technology, and Dr Morven Duncan – Applications Development).

Professor Russell Morris, Chief Scientific Officer, MOFgen Ltd said:

“We are delighted to secure this investment as we really believe that our technology will make a significant and positive difference for those people who suffer from chronic wounds and secondary infections.”

Professor Verity Brown, Vice Principal Enterprise and Engagement, University of St Andrews, said:

“The team’s world-leading research into MOFs has been supported by funding from the University, Scottish Enterprise, The Royal Society and the European Research Council. We are thrilled that investors have recognised the commercial potential of the spin-out company, MOFgen.”

Paul Devlin, Investment Manager for Scotland at Mercia, said:

“MOFgen is another example of the high-quality research and technology that Scottish universities are developing.  The MOF technology has already won several awards, secured grant funding and received interest from commercial partners in the medical devices industry.

“The investment supplied by Mercia and the Scottish Investment Bank will help the new business to continue validating its technology and build commercial traction in its initial target markets.”

This news article was featured in several news outlets including:

MOFgen Wins First Prize in the RSC Emerging Technologies Competition

MOFgen Wins First Prize in the RSC Emerging Technologies Competition

MOFgen Ltd has won first prize in the prestigious Royal Society of Chemistry Emerging Technologies Competition, Health and Wellbeing category.

Stewart Warrender and Morven Duncan from MOFgen fought off stiff competition from nine other finalists from universities and spin-out companies from across Europe with their pitch to a panel of international investors and industry experts.

MOFgen are commercialising porous metal organic frameworks for the delivery of nitric oxide from coatings on medical devices and wound dressings – technology that was originally invented by Prof Russel Morris FRS and Dr Paul Wheatley of the School of Chemistry, St Andrews. The technology will reduce healthcare associated infections and procedural complications, and speed up wound healing rates.

The judges recognised the major impact this technology can make to the medical device and wound care markets and were impressed by the team’s clear commercialisation strategy.

Russell Morris wins Peter Day Award 2015

Russell Morris Wins Peter Day Award 2015

Professor Russell Morris, professor of Structural and Materials Chemistry at the University of St Andrews, has been awarded the Royal Society of Chemistry 2015 Peter Day Award for his pioneering work on the chemistry of porous solids.

Professor Morris works in developing specific types of new materials that are solid but have tiny gaps or channels through them that are wide enough for molecules of other substances to pass through. Some of these kinds of materials are already used in everyday products like water softeners and household detergents. His research group and spin out company MOFgen create and develop new materials with similar properties that can help medicine by speeding up the wound healing process or preventing bacterial infections on medical devices.

Prof Russell Morris receiving the Brian Mercer Award, presented by HRH The Duke of York

New Wound Healing Technology Wins Royal Society Innovation Prize

New technology that could significantly improve wound healing in people such as those suffering from diabetes, the elderly and the obese, as well as greatly cut the cost to the NHS associated with treating such wounds, has been awarded the Royal Society Brian Mercer Award for Innovation 2012

Professor Russell Morris, from the University of St Andrews, has used an exciting development in chemical technology – metal-organic frameworks (MOFs) – to apply small, beneficial amounts of the gas, nitric oxide, to wounds safely in order speed up healing. He will receive his prize at a special event at the Royal Society today (5 December 2012). Nitric oxide is a simple gas molecule which in large amounts is significantly toxic; however in small amounts it has essential roles in the body, such as controlling blood pressure in the cardiovascular system and also in wound healing.

When a wound occurs in normal skin the body produces nitric oxide to fight infection through its antibacterial properties and then to signal the production of new blood vessels to increase blood flow to the damaged area. Unfortunately people who suffer from diabetes, or those who are elderly or obese often don’t produce enough nitric oxide naturally which can lead to poor wound healing. In bad cases, such as chronic wounds which do not heal, the affected limbs may need to be amputated.

Among chronic wounds the highest prevalence lays in the venous leg ulcer (VLU), diabetic foot/leg wound (DFU) and pressure ulcer (PU) categories. Estimates of annual VLU incidence in the US reach nearly 1 million. In 2010-11, the NHS in England spent an estimated £639 million–£662 million, 0.6–0.7% of its budget on diabetic foot ulceration and amputation. Patients with type I or II diabetes have a 1-4% annual chance of foot ulceration and a lifetime risk that may be as high as 25%. Estimates for the UK indicate that 15% of all diabetes patients develop DFUs and that 84% of lower leg amputations are caused by DFUs.

There is strong evidence that the addition of nitric oxide to wounds can be extremely beneficial in these situations. However because nitric oxide is a toxic gas there needs to be a method of applying small, beneficial amounts of gas safely to a wound.

The MOFs that Professor Morris is working on offer an opportunity to do just this.  These solids are extremely porous and have a very large internal surface area and can store large quantities of gas safely. Professor Morris and his team are developing non toxic MOFs to be incorporated into wound dressings which deliver nitric oxide slowly and at levels which do not cause any toxic or inflammatory effects but show beneficial effect of improved wound healing.

Professor Russell Morris said of his work:

“The highly porous metal-organic frameworks act as miniature gas tanks, allowing us to deliver only safe and beneficial amounts of nitric oxide from something as easy to use as a wound dressing. This will transform how we can use this gas to help people with debilitating chronic wounds.”

Professor Morris will receive just under £200,000 from the Royal Society to develop the technology further so that it can be put into clinical trials. The Brian Mercer Award for Innovation is a scheme for scientists who wish to develop an already proven concept or prototype into a near-market product ready for commercial exploitation. Professor Morris has already benefited from Royal Society support including a University Research Fellowship (1998-2006), Wolfson Research Merit Award (2009-2010), the Brian Mercer Feasibility Award (2008) and a current Industry Fellowship.